Drug intelligence / Profile preview

glutazumab

Development stage: Unknown
Lead developer: Gmax Biopharm
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Glutazumab is a novel long-acting fusion protein that combines a glucagon-like peptide-1 (GLP-1) derivative with a humanized GLP-1 receptor (GLP-1R) monoclonal antibody via a peptide linker. It acts as a GLP-1 receptor agonist and exerts anti-diabetic effects by specifically binding to and activating the GLP-1 receptor. Preclinical studies demonstrated that glutazumab lowers blood glucose levels, improves β-cell function, and ameliorates dyslipidemia in animal models of type 2 diabetes. Its unique structure allows for prolonged activity compared to other GLP-1 analogs. Glutazumab has shown favorable safety profiles in early clinical trials compared to dulaglutide. The drug is being investigated primarily for the treatment of type 2 diabetes mellitus.

Other names: gulgafafusp alfa

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on glutazumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glutazumab.

Explore the full profile